Merck & Co Inc

NYSE:MRK   3:59:59 PM EDT
+1.58 (+2.02%)
4:00:00 PM EDT: $79.84 -0.03 (-0.04%)
Products, Strategic Combinations

Hitgen Announces License Agreement With Merck & Co, Kenilworth To Access Compounds For Potential Development Of A Novel Class Of Drugs

Published: 12/21/2020 16:52 GMT
Merck & Co Inc (MRK) - Hitgen Announces License Agreement With Merck & Co.
, Inc., Kenilworth, Nj USA to Access Compounds for Potential Development of a Novel Class of Drugs.
Hitgen Inc - Financial Terms of License Are Not Disclosed.
Hitgen Inc - Will Grant Exclusive Rights to Merck & Co Inc to Develop & Commercialize Licensed Compounds.
Hitgen Inc - Will Be Eligible for Preclinical & Clinical Milestone Payments As Project Progresses, in Addition to License Fee.